Following this evidence, the rationale for combining CSF-1R blocking antibodies with PARP inhibitors led to reprogramming of the TME and significantly enhanced innate and adaptive anti-tumour immunity, which was CD8+-mediated in BRCA-deficient tumours in vivo (191). The gene discussed is CSF1R; the disease is neoplasm.